Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

• Status: Unknown status
• Trial end date: 2020-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and efficacy of Busulfan/FLAG (fludarabine, cytarabine and granulocyte colony-stimulating factor) Conditioning Regimen in Patients with Relapsed/refractory Acute Leukemia undergoing allogeneic peripheral blood stem cell transplantation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese PLA General Hospital
• Collaborators: 309th Hospital of Chinese People's Liberation Army; Beijing Naval General Hospital; Space Center Hospital, Peking University
• Treatments: Busulfan; Cytarabine; Fludarabine; Fludarabine phosphate; Lenograstim; Sargramostim; Thymoglobulin; Vidarabine

Criteria

Inclusion Criteria:

• relapsed/refractory acute leukemia regardless of cytogenetics

• All patients should aged 12 to 65 years

• Have matched sibling donors, ≥8/10 HLA(human leukocyte antigen) matched unrelated donors or haploidentical donors

• Patients without any uncontrolled infections or without severe pulmonary, renal, hepatic or cardiac diseases

Exclusion Criteria:

• Patients aged less than 12 years old

• Patients with any uncontrolled infections or with severe pulmonary, renal, hepatic or cardiac diseases

• Acute myeloid leukemia patients with t (15;17)